New advances in treatment of dry eye disease

[New formulations for dry eye treatment].

Dry Eye Disease

Dry eye disease (DED) is a clinically significant multifactorial disorder of the ocular surface and tear film as it results in ocular discomfort and visual impairment and predisposes the cornea to infections. It is important for the quality of life and tends to be a chronic disease. It is also common, as the prevalence is estimated between 5 % to 30 % and this increases with age. Therefore, it ...

Biomarkers In Dry Eye Disease

Dry eye disease is a multifactorial chronic disorder of the ocular surface that affects up to 100 million people worldwide. During the pathogenesis of dry eye, impaired function of the lacrimal and meibomian glands results in hyposecretion of aqueous tear fluid, coupled with increased evaporation and instability of the tear film, which becomes increasingly hyperosmolar in character at more seve...

Lifitegrast: A novel drug for treatment of dry eye disease

Dry eye disease (DED) is an inflammatory disorder of ocular surfaces leading to severe disability, especially in the elderly age group. The mainstay of therapy includes artificial tears, punctual plugs, topical anti-inflammatory agents, and corticosteroids. In the past few years, only cyclosporine-A emulsions have been added to the existing therapy, but it is discontinued by most patients as it...

Etiology, prevalence, and treatment of dry eye disease

PURPOSE This review article examines the prevalence, etiology, and current therapies of dry eye disease, with special focus on postmenopausal women. METHOD A systematic literature search utilizing MEDLINE was conducted to identify peer-reviewed articles related to dry eye published prior to September 2008. The terms "dry eye" and "women" were searched in combination with one or more of the fo...